External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: A population-based study

The Lancet Oncology

Volumn 14, Issue 2, 2013, Pages 141-148

  Heng, Daniel YC ^a   Xie, Wanling ^b   Regan, Meredith M ^b   Harshman, Lauren C ^c   Bjarnason, Georg A ^d   Vaishampayan, Ulka N ^e   Mackenzie, Mary ^f   Wood, Lori ^g   Donskov, Frede ^h   Tan, Min Han ⁱ   Rha, Sun Young ^j   Agarwal, Neeraj ^k   Kollmannsberger, Christian ^l   Rini, Brian I ^m   Choueiri, Toni K ^b  

^a TOM BAKER CANCER CENTRE   (Canada)

^b HARVARD UNIVERSITY   (United States)

^c STANFORD CANCER INSTITUTE   (United States)

^d Sunnybrook Odette Cancer Center   (Canada)

^e WAYNE STATE UNIVERSITY   (United States)

^f LONDON HEALTH SCIENCES CENTRE   (Canada)

^g QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^h AARHUS UNIVERSITY HOSPITAL   (Denmark)

ⁱ INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY   (Singapore)

^j Yonsei University   (South Korea)

^k UNIVERSITY OF UTAH   (United States)

^l BRITISH COLUMBIA CANCER AGENCY   (Canada)

^m TAUSSIG CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; BEVACIZUMAB; PAZOPANIB; SORAFENIB; SUNITINIB;

ACCURACY; ADULT; ANEMIA; ARTICLE; BRAIN METASTASIS; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERCALCEMIA; INTERMETHOD COMPARISON; KARNOFSKY PERFORMANCE STATUS; KIDNEY CARCINOMA; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOLECULARLY TARGETED THERAPY; NEPHRECTOMY; NEUTROPHILIA; OVERALL SURVIVAL; POPULATION MODEL; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; THROMBOCYTOSIS; VALIDATION STUDY;

AGED; CARCINOMA, RENAL CELL; DATABASES, FACTUAL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SURVIVAL RATE;

EID: 84873080330     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70559-4     Document Type: Article

References (24)

1. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
2. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
3. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370:2103-2111.
4. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010, 28:2137-2143.
5. Sternberg CN, Szczylik C, Lee E, et al. A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 2009, 27(suppl). abstr 5021.
6. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011, 378:1931-1939.
7. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009, 27:5794-5799.
8. Heng DY, Xie W, Bjarnason GA, et al. A unified prognostic model for first- and second-line targeted therapy in metastatic renal cell carcinoma (mRCC): results from a large international study. Proc Am Soc Clin Oncol 2010, 28(suppl). abstr 4523.
9. Choueiri TK, Garcia JA, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 2007, 110:543-550.
10. Escudier BJ, Ravaud A, Negrier S, et al. Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis. Proc Am Soc Clin Oncol 2008, 26(suppl). abstr 5025.
11. Negrier S, Escudier B, Gomez F, et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. Ann Oncol 2002, 13:1460-1468.
12. Manola J, Royston P, Elson P, et al. Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clin Cancer Res 2011, 17:5443-5450.
13. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002, 20:289-296.
14. Pencina MJ, D'Agostino RB Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 2004, 23:2109-2123.
15. Allison PD Survival analysis using the SAS system: a practical guide 1995, SAS Institute, Cary.
16. Cook NR, Ridker PM Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med 2009, 150:795-802.
17. Pencina MJ, D'Agostino RBS, D'Agostino RB, Vasan RS Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008, 27:157-172.
18. Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 2009, 338:b2393.
19. Rubin DB Multiple imputation for nonresponse in surveys 1987, Wiley, New York.
20. Heng DY, Choueiri TK, Lee JL, et al. An in-depth multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) that do not meet eligibility criteria for clinical trials. Proc Am Soc Clin Oncol 2012, 30(suppl). abstr 4536.
21. Op den Winkel M, Nagel D, Sappl J, et al. Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort. PLoS One 2012, 7:e45066.
22. Buyyounouski MK, Pickles T, Kestin LL, Allison R, Williams SG Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer. J Clin Oncol 2012, 30:1857-1863.
23. Tang PA, Vickers MM, Heng DY Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far. Hematol Oncol Clin North Am 2011, 25:871-891.
24. van der Veldt AA, Eechoute K, Gelderblom H, et al. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res 2011, 17:620-629.